Full Text
The Full Text of this article is available as a PDF (35.2 KB).
editorial . 2000 Jul 3;83(3):281–283. doi: 10.1054/bjoc.2000.1342
Changes in18F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got?
P Price
1
P Price
1CRC PET Oncology group, MRC Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, London, UK
Find articles by P Price
1CRC PET Oncology group, MRC Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, London, UK
Issue date 2000 Jul.
Copyright © 2000 Cancer Research Campaign
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
PMCID: PMC2374563 PMID: 10917538